The nasal spray, Spravato® (esketamine), is covered when deemed medically necessary to treat beneficiaries with treatment-resistant depression and other US Food and Drug Administration (FDA)-approved indications, which are available in the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. This benefit is covered under the medical benefit, not pharmacy, and prior authorization is required.
While Walgreens is not a network provider at this time, prescriptions for Spravato (esketamine) can be filled through Walgreens Specialty Pharmacy.
See the TRICARE Policy Manual (TPM) Chapter 7, Section 3.8, Paragraph 5.2.14 for more information.
